Spain approves Phase 2a trial of HT-001 showing reduced skin toxicities in cancer patients on EGFR inhibitors

Hoth Therapeutics secured regulatory approval in Spain for its Phase 2a CLEER Trial of HT-001, a topical treatment aimed at reducing skin toxicities caused by EGFR inhibitor cancer therapies. Interim results show over 65% of patients experienced significant relief from rash, pain, and itching, with no need to reduce or stop their cancer treatment. The trial's success supports Hoth's plan to expand the study across Europe, potentially improving quality of life and treatment adherence for cancer patients. This marks a key step in developing supportive care options in oncology.